Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Kinase Inhibitors | 10 | 2023 | 5672 | 0.710 |
Why?
|
| Carbazoles | 1 | 2015 | 220 | 0.460 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2023 | 1626 | 0.410 |
Why?
|
| Parkinson Disease | 2 | 2023 | 2878 | 0.380 |
Why?
|
| Alkenes | 1 | 2010 | 54 | 0.350 |
Why?
|
| Azo Compounds | 1 | 2010 | 117 | 0.340 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2019 | 76 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 2048 | 0.300 |
Why?
|
| Copper | 1 | 2010 | 367 | 0.290 |
Why?
|
| Piperidines | 1 | 2015 | 1655 | 0.280 |
Why?
|
| Peptides | 1 | 2019 | 4354 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3492 | 0.280 |
Why?
|
| Organometallic Compounds | 1 | 2010 | 646 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5319 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase 8 | 2 | 2023 | 48 | 0.220 |
Why?
|
| Dibenzazepines | 1 | 2022 | 26 | 0.210 |
Why?
|
| Molecular Structure | 3 | 2019 | 1878 | 0.210 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 13382 | 0.190 |
Why?
|
| Neuroblastoma | 2 | 2023 | 1248 | 0.190 |
Why?
|
| Pyrrolidines | 1 | 2022 | 338 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2020 | 184 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2020 | 112 | 0.170 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 226 | 0.150 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2019 | 431 | 0.140 |
Why?
|
| Phosphorylation | 3 | 2023 | 8311 | 0.140 |
Why?
|
| Models, Animal | 1 | 2023 | 2109 | 0.140 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 655 | 0.130 |
Why?
|
| Receptors, Mitogen | 1 | 2015 | 61 | 0.130 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 669 | 0.110 |
Why?
|
| Quinolines | 1 | 2019 | 764 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2020 | 1606 | 0.110 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 3074 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2018 | 1697 | 0.110 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 16967 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2018 | 1088 | 0.100 |
Why?
|
| Ligands | 1 | 2019 | 3268 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2018 | 3087 | 0.100 |
Why?
|
| Proteome | 1 | 2020 | 1857 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 13635 | 0.090 |
Why?
|
| Alkylation | 1 | 2010 | 84 | 0.090 |
Why?
|
| Point Mutation | 1 | 2015 | 1595 | 0.090 |
Why?
|
| Animals | 8 | 2023 | 168201 | 0.090 |
Why?
|
| Stereoisomerism | 1 | 2010 | 613 | 0.080 |
Why?
|
| Catalysis | 1 | 2010 | 773 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1405 | 0.080 |
Why?
|
| Mutation | 5 | 2023 | 30016 | 0.070 |
Why?
|
| Cell Line | 2 | 2020 | 15576 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 2644 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 2222 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 10754 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3607 | 0.070 |
Why?
|
| Catalytic Domain | 2 | 2018 | 704 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2023 | 5304 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 3705 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 1827 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9277 | 0.060 |
Why?
|
| Crystallography, X-Ray | 2 | 2019 | 1989 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 18221 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 22115 | 0.050 |
Why?
|
| Humans | 16 | 2023 | 760617 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 638 | 0.040 |
Why?
|
| Adenylyl Imidodiphosphate | 1 | 2019 | 18 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2019 | 23416 | 0.040 |
Why?
|
| Databases, Protein | 1 | 2020 | 387 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 717 | 0.040 |
Why?
|
| Dimerization | 1 | 2019 | 890 | 0.040 |
Why?
|
| Lung | 1 | 2015 | 9998 | 0.030 |
Why?
|
| Mice | 3 | 2022 | 81368 | 0.030 |
Why?
|
| Exons | 1 | 2022 | 2381 | 0.030 |
Why?
|
| Protein Binding | 2 | 2019 | 9345 | 0.030 |
Why?
|
| Tyrosine | 1 | 2019 | 1440 | 0.030 |
Why?
|
| Lysine | 1 | 2019 | 993 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 1608 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 465 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 2625 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2020 | 1320 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 733 | 0.030 |
Why?
|
| Cell Division | 1 | 2020 | 4457 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2017 | 982 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 1646 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2022 | 2553 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 1894 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2019 | 3965 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 2057 | 0.020 |
Why?
|
| Cell Survival | 1 | 2019 | 5780 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2019 | 3027 | 0.020 |
Why?
|
| Proteomics | 1 | 2020 | 3836 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9529 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2020 | 12758 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 14389 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4849 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2015 | 10432 | 0.010 |
Why?
|
| Adult | 2 | 2023 | 220969 | 0.010 |
Why?
|
| Female | 3 | 2020 | 392148 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 59179 | 0.010 |
Why?
|
| Male | 2 | 2020 | 360358 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 220584 | 0.000 |
Why?
|
Concepts
(97)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(25)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_